China’s NMPA cleared multiple differentiated therapies and early-stage candidates for clinical use, including CSPC’s SYH-2083 for dry eye disease and Innocare’s ADC ICP-B381 for solid tumors such as prostate cancer. These approvals extend the pipeline of ophthalmic products and oncology antibody-drug conjugates entering clinical evaluation. In separate NMPA updates, Everest Medicines’ Cardamyst (for paroxysmal supraventricular tachycardia) and Simcere’s Yingmule RSV long-acting monoclonal antibody for newborns and infants also received approval, signaling regulatory momentum in infectious disease prevention and differentiated cardiology. For biotech operators, the value of these clearances is speed to clinical generation of safety and early efficacy datasets, which can influence subsequent partnering and investment decisions. It also reflects the broadening of China’s approval portfolio across modalities. Collectively, the announcements indicate sustained throughput for NMPA approvals across oncology, immunology, and supportive prevention indications.